Huahai pharmaceutical passed the consistency evaluation according to the "original research technology transfer" of feiwelun tablets

Recently, Huahai pharmaceutical industry issued an enterprise announcement, saying that on December 29, 2018, the State Drug Administration issued the circular on the catalogue of generic reference preparations (the 19th batch) (the 135th batch in 2018) Yifeiwelun tablets (specification: 50mg, 200mg, 600mg) produced by Zhejiang Huahai Pharmaceutical Co., Ltd were included in the list due to the "transfer of original research technology" Recently, yifeiwelun tablets officially entered the list of drugs listed in China, marking that yifeiwelun tablets passed the consistency evaluation of quality and efficacy of generic drugs Eferene tablets are suitable for the treatment of HIV-1 infection in adults, adolescents and children Enfeveren tablets were developed by Merck and first listed in the European Union in May 1999 and in China in 2005 In 2013, Merck transferred yifeiwelun tablets (trade name: stocrin ®) to Huahai pharmaceutical The company started the consistency evaluation of yifeiwelun tablets in May 2016 In December 2016, Zhejiang Pharmaceutical Industry Association submitted the reference preparation recommendation application to the generic consistency evaluation office, which was approved by the State Food and Drug Administration on December 29, 2018 From January to September 2018, the company's domestic sales revenue of yifeiwelun tablets was about 102.2108 million yuan, and the main domestic manufacturers were Zhejiang Huahai Pharmaceutical Co., Ltd and Shanghai desino biomedical Co., Ltd Since yifeiwelun tablet is a national fixed-point quantitative purchase product, the company has not yet found reliable domestic market sales data of the product from the relevant database Up to now, the company's domestic R & D application fee for non wellen film project is about 210.92 million yuan According to the pharmaceutical intelligence data, up to now, there are 20 products (12 varieties) of Huahai pharmaceutical industry that have passed or are deemed to have passed the consistency evaluation Yifeiwelun tablet is the twelfth product that has passed the consistency evaluation of the company Huahai pharmaceutical industry consistency evaluation details